Thierry Dervieux

PharmGKB Update: II. CYP3A5, Cytochrome P450, Family 3, Subfamily A, Polypeptide 5

E. Cook, M. Boguski, F. Behm, 2004, Pharmacological Reviews.

Pharmacogenetics and cancer therapy

Mary V. Relling, M. Relling, T. Dervieux, 2001, Nature Reviews Cancer.

Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia

S. Shurtleff, F. Behm, S. Raimondi, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia

M. Relling, C. Pui, W. Evans, 2009, Clinical pharmacology and therapeutics.

De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.

M. Relling, C. Pui, W. Evans, 2002, Blood.

HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy.

M. Relling, C. Pui, W. Evans, 2002, Clinical chemistry.

Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.

M. Relling, M. Roussel, E. Vanin, 2001, Cancer research.

Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.

F. Behm, S. Raimondi, M. Relling, 2002, Pharmacogenetics.